Thomas Decaens, Françoise Roudot‐Thoraval, Solange Bresson‐Hadni, Carole Meyer, Jean Gugenheim, Francois Durand, Pierre‐Henri Bernard, Olivier Boillot, Karim Boudjema, Yvon Calmus, Jean Hardwigsen, Christian Ducerf, Georges Philippe Pageaux, Sebastien Dharancy, Olivier Chazouilleres, Daniel Dhumeaux, Daniel Cherqui, Christophe Duvoux – 22 June 2005 – The actual impact of transarterial chemoembolization before liver transplantation (LT) for hepatocellular carcinoma (HCC) on patient survival and HCC recurrence is not known.

Thierry Thevenot, Claire Vanlemmens, Vincent Di Martino, Marie‐Claude Becker, Pierre‐Olivier Denue, Bernadette Kantelip, Solange Bresson‐Hadni, Bruno Heyd, Georges Mantion, Jean‐Philippe Miguet – 22 June 2005 – Liver involvement in hereditary hemorrhagic telangiectasia may lead to high‐output cardiac failure. Few data have been reported on orthotopic liver transplantation (OLT) for these patients. In this paper, we describe two patients treated by OLT as a salvage procedure for cardiac failure, and we review literature on this subject.

Kalpana Reddy, Susan Mallett, Tim Peachey – 22 June 2005

Rajiv Jalan, Sambit Sen, Christian Steiner – 22 June 2005

Jorge Reyes – 22 June 2005

Matthew Jacob, James D. Lewsey, Carlos Sharpin, Alexander Gimson, Mohammed Rela, Jan H.P. van der Meulen – 22 June 2005 – A model that can accurately predict post–liver transplant mortality would be useful for clinical decision making, would help to provide patients with prognostic information, and would facilitate fair comparisons of surgical performance between transplant units.

David P. Breen, Anthony M. Marinaki, Monica Arenas, Peter C. Hayes – 22 June 2005 – Azathioprine (AZA) is a thiopurine prodrug commonly used in triple‐immunosuppressive therapy following liver transplantation. Approximately 1 in 10 patients suffers side effects in response to the drug, the most problematic being bone marrow toxicity. There is evidence that polymorphisms in the genes encoding thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPase) predict adverse drug reactions to AZA therapy.

Nicholas Onaca, Solly Mizrahi, Nathan Bar Nathan, Idan Burstein, Eytan Mor – 22 June 2005

John A. Goss, Philip Seu, Feng Qin Gao, Samuel Wyllie – 22 June 2005 – The recently identified acute‐phase response antimicrobial peptide hepcidin has been postulated to maintain iron homeostasis by modulating iron absorption at both the intestinal and macrophage levels. Hepcidin has also been reported to be responsible for anemia associated with chronic inflammatory diseases, and in anemia in patients with hepatic adenomas.

Chung Mau Lo, Chi Leung Liu, George K. Lau, See Ching Chan, Irene O. Ng, Sheung Tat Fan – 22 June 2005 – Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation. Emergence of lamivudine‐resistant YMDD mutant is common. We report the results of liver transplantation in 16 patients with pretransplantation YMDD mutants after receiving lamivudine treatment for a median of 738 days (range, 400‐1799 days).